A fascinating Lancet RCT shows once-weekly semaglutide may redefine alcohol use disorder treatment. 🎯

In 108 adults with AUD and obesity, semaglutide reduced heavy drinking days by –13.7 percentage points vs placebo (p=0.0015) and improved craving, consumption, and biomarkers. 📉

With an NNT of ~4.3 and a manageable safety profile, GLP-1 therapy signals a shift from abstinence to precision harm reduction. 💡

Efficacy. Safety. Meaningful impact.

Is this the beginning of a new era in addiction medicine? 🧠💉